Goldenwell Biotech, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $7,985 for the three months ending September 30, compared to a loss of $23,065 during the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $47,581, a significant improvement from the $103,962 loss reported in the prior year. The company generated service revenue of $25,000 in the third quarter and $62,500 for the nine-month period, marking a notable increase from zero revenue in the same periods of 2024.
The company’s total assets as of September 30, 2025, were $220,410, a slight decrease from $224,192 at the end of 2024. Current liabilities surged to $39,360, primarily due to an increase in unearned service revenue, which rose to $37,500 from zero in the previous year. Total liabilities increased to $315,233, up from $271,433 at the end of 2024, while stockholders' equity fell to $(94,823) from $(47,241), reflecting ongoing operational losses.
In terms of operational developments, Goldenwell Biotech has not reported any significant changes in customer counts or product adoption rates. The company continues to focus on its research and development efforts in the healthcare and supplements sector, although it has yet to establish a manufacturing facility. The management indicated that approximately $5 million in funding would be necessary to complete the construction of manufacturing facilities and train the workforce, which is expected to take about one year.
Looking ahead, Goldenwell Biotech's management expressed concerns regarding the company's ability to continue as a going concern, emphasizing the need for additional capital to fund operations and achieve profitability. The company plans to pursue equity financing to raise the necessary funds, although there is no assurance that it will be successful in these efforts. The management's outlook remains cautious, as the company has not generated positive cash flows from operations and continues to face significant financial challenges.
About GOLDENWELL BIOTECH, INC.
Goldenwell Biotech, Inc. is an early-stage company focused on research, development, and production of nutraceuticals and dietary supplements. It licenses proprietary technology for health products, including peptides and plant extracts, targeting health-conscious consumers. The company operates with minimal assets, relies on external financing, and emphasizes innovation in bioactive health solutions within the wellness market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.